MedPath

KUKJEON PHARMACEUTICAL Co., Ltd.

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Evaluate Tolerability and Safety of HY209 in Healthy Volunteers

Phase 1
Conditions
Dementia
Interventions
Drug: HY-209 placebo
First Posted Date
2024-08-01
Last Posted Date
2024-08-15
Lead Sponsor
Kukjeon Pharmaceutical Co.,Ltd.
Target Recruit Count
59
Registration Number
NCT06533878
Locations
🇰🇷

Kukjeon Pharmaceutical Co., Ltd., Anyang-Si, Gyeonggi-Do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath